Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)
收藏Mendeley Data2026-04-09 收录
官方服务：
资源简介：
Supplementary Information to accompany and support the manuscript: Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.
提供机构：
Meredith Whitaker
